# Medtronic plc (MDT) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/MDT
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Sep 6, 2026

Medtronic plc (MDT) last closed at $94.17, in the upper half of its 52-week range of $73.31–$106.33. Composite market sentiment across 1 analysis is positive (+23 on a −100 to +100 scale), as of Sep 6, 2026.

## What the data says

At $94.17, Medtronic trades in the upper-middle portion of its 52-week range of $73.31 to $106.33 — roughly 11% below the high and about 28% above the low. That range spans a little over $33, or about 45% of the low, which is a fairly contained band for a full year of trading and points to a stock that has moved without the wide swings seen in more volatile parts of the market. The beta of 0.57 is consistent with that: the shares have historically moved about half as much as the broad market.

The market capitalization of roughly $120 billion carries a trailing price-to-earnings ratio of 23.2 against a forward multiple of 14.7, a gap that reflects expectations of meaningfully higher earnings ahead rather than any change in the current price. Price-to-book sits at 2.44. On the underlying business, the profit margin is 13.9% and revenue growth is 13.7%, so roughly one dollar in seven of sales currently reaches the bottom line while the top line expands at a similar rate. The dividend yield of 3.06% means a substantial share of the total return currently comes as cash paid out rather than price movement alone.

Recent news flow is split between the company and the wider medical device sector. Company-specific coverage clusters around the first-quarter earnings report — previews of Wall Street's key metric projections beforehand, breakdowns of the reported metrics afterward, and several pieces relaying broker views on the stock. The rest is industry-level: market forecasts for renal denervation and for atrial fibrillation treatment devices, where Medtronic appears alongside Abbott, Boston Scientific, Johnson & Johnson, and AtriCure, plus commentary on growth trends at Intuitive Surgical. That balance means part of what has been written about Medtronic lately is really about the competitive categories it operates in rather than the company itself.

## About Medtronic plc

Medtronic plc designs, manufactures, and sells device-based medical therapies for hospitals, physicians, clinicians, and patients worldwide. Founded in 1949 and now headquartered in Galway, Ireland, the company organizes its business into three portfolios: Cardiovascular, Neuroscience, and Medical Surgical.

The Cardiovascular portfolio covers cardiac rhythm management devices such as pacemakers, defibrillators, and resynchronization therapy systems, along with cardiac ablation products, insertable monitors, heart valves and repair products, endovascular stent grafts, coronary and peripheral intervention products, and related remote monitoring software. The Neuroscience portfolio serves spinal and neurological surgery and pain management, including spinal implants and biologics, spinal cord stimulation and brain modulation systems, implantable drug infusion pumps, nerve ablation, and ear, nose, and throat products. The Medical Surgical portfolio spans surgical stapling and vessel sealing instruments, wound closure and electrosurgery products, robotic-assisted surgery and surgical video analytics, hernia and gynecology products, gastrointestinal diagnostics and therapies, patient monitoring and airway management, and diabetes products such as insulin pumps and continuous glucose monitoring systems.

## Company profile

- Symbol: MDT
- Exchange: NYSE
- Security type: Stock
- Sector: Healthcare
- Industry: Medical Devices
- Composite sentiment: positive (23 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $120.46B |
| Enterprise value | $140.41B |
| Trailing P/E | 23.19 |
| Forward P/E | 14.72 |
| Price to book | 2.44 |
| Price to sales | 3.21 |
| Dividend yield | 3.06% |
| Beta | 0.57 |
| Net margin | 13.93% |
| Revenue growth | 13.70% |
| Earnings growth | 40.70% |
| 52-week high | $106.33 |
| 52-week low | $73.31 |
| Average volume | 8.21M |

## Related stocks

- [STE](https://synoptiv.com/stock/STE)
- [TRIB](https://synoptiv.com/stock/TRIB)
- HBCN.IR

## Recent news

- [Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?](https://www.fool.com/investing/2026/09/05/intuitive-surgicals-growth-has-cooled-from-its-pos/?source=iedfolrf0000001) — Sep 5, 2026
- [Medtronic (NYSE:MDT) Flashes a High-Quality Breakout Setup](https://www.chartmill.com/news/MDT/Chartmill-54436-Medtronic-NYSEMDT-Flashes-a-High-Quality-Breakout-Setup) — Sep 5, 2026
- [How Much Upside Can BSX Stock's Growth Deliver?](https://www.trefis.com/articles/614380/how-much-upside-can-bsx-stocks-growth-deliver/2026-09-04) — Sep 4, 2026
- [Was JNJ Stock Rally Actually Its Own?](https://www.trefis.com/articles/614430/was-jnj-stock-rally-actually-its-own/2026-09-04) — Sep 4, 2026
- [Apple's John Ternus needs to be his own type of CEO and 'not Tim Cook 2'](https://finance.yahoo.com/video/apples-john-ternus-needs-to-be-his-own-type-of-ceo-and-not-tim-cook-2-203847038.html) — Sep 4, 2026
- [Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)](https://www.globenewswire.com/news-release/2026/09/04/3356656/28124/en/renal-denervation-market-size-share-trends-analysis-global-opportunity-analysis-and-industry-forecast-2026-2036.html) — Sep 4, 2026
- [Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?](https://finance.yahoo.com/healthcare/articles/boston-scientifics-icvt-business-gains-142700121.html) — Sep 4, 2026
- [Medtronic executives to speak at upcoming investor conferences](/news/389140/medtronic-executives-to-speak-at-upcoming-investor-conferences) — Sep 4, 2026
- [These stocks in the red-hot healthcare sector have gotten too crowded to own](https://www.marketwatch.com/story/these-stocks-in-the-red-hot-healthcare-sector-have-gotten-too-crowded-to-own-b4b2e0bc?mod=mw_FV) — Sep 3, 2026
- [4 Reasons to Buy Medtronic Stock Like There's No Tomorrow](https://www.fool.com/investing/2026/09/03/x-reasons-to-buy-hot-ticker-like-theres-no-tomorro/?source=iedfolrf0000001) — Sep 3, 2026

## Frequently asked questions

### What is the current market sentiment for MDT?

As of Sep 6, 2026, Medtronic plc (MDT) carries positive (+23 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has MDT stock been performing?

Medtronic plc last closed at $94.17, in the upper half of its 52-week range of $73.31–$106.33.

### What is MDT's market cap and valuation?

Medtronic plc has a market capitalization of about $120.46B, a trailing P/E of 23.2, a dividend yield of 3.06%.

### What sector is MDT in, and who are its competitors?

Medtronic plc operates in the Healthcare sector, specifically Medical Devices. Comparable companies include STE, TRIB, HBCN.IR.

### Where can I find a full analysis of MDT?

The full MDT report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/MDT/v/1) (account and access required)